Should localized prostate cancer in the favourable group no longer be treated?

In contrast to abstention-surveillance, active surveillance is a curative management modality. It aims at delaying the treatment of a less aggressive tumor until it becomes aggressive while remaining within the window of curability of the disease. Through a reading of the literature, we will tr...

Full description

Bibliographic Details
Published in:	Batna Journal of Medical Sciences
Main Authors:	Kamel Hamizi, Souad Aouidane
Format:	Article
Language:	Arabic
Published:	Algerian Society of Clinical & Oncological Pharmacy 2022-01-01
Subjects:	prostate as gleason psa favorable group
Online Access:	https://batnajms.net/wp-content/uploads/Archives/2021/2/13_BJMS_8_2_Hamizi.pdf

Similar Items

Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer
by: Gelareh Vahabzadeh, et al.
Published: (2025-01-01)

Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups
by: Mohamed O. Andarawi, et al.
Published: (2025-02-01)

Clinical and histopathological characteristics of prostate cancer in Erbil city/ Iraq
by: Narin Shakir Mola ahmed, et al.
Published: (2024-12-01)

Bone scintigraphy in staging of newly diagnosed prostate cancer in regard of different risk groups
by: Sabina Sevcenco, et al.
Published: (2019-06-01)

Correlation between total prostate specific antigen and histological grading of prostate cancer in Kenyan mission hospital: a five-year retrospective review
by: Chinonso Paul Shu, et al.
Published: (2025-05-01)

The Relationship Between Family History of Prostate Cancer and Prostate Cancer Risk at the Time of Diagnosis in Babol City
by: Shayan Salehi, et al.
Published: (2024-02-01)

Expression And Scoring Of HER2/Neu in Variants of Prostate Adenocarcinoma
by: Santosh Kumar Sidhwani, et al.
Published: (2021-03-01)

The correlation of e-cadherin expression with the modified gleason score and the grade group of prostatic adenocarcinoma
by: Sakar Azad Hayder, et al.
Published: (2021-01-01)

Influence of Active Surveillance on Gleason Score Upgrade and Prognosis in Low- and Favorable Intermediate-Risk Prostate Cancer
by: Xuanhan Hu, et al.
Published: (2022-10-01)

Efficacy of PSMA PET/CT radiomics analysis for risk stratification in newly diagnosed prostate cancer: a multicenter study
by: Esmail Jafari, et al.
Published: (2025-09-01)

Comparison of data fusion strategies for automated prostate lesion detection using mpMRI correlated with whole mount histology
by: Deepa Darshini Gunashekar, et al.
Published: (2024-07-01)

PROSTAT KANSERİ TANISINDA PROSTAT SPESİFİK ANTİJENİN (PSA) ÖNEMİ
by: Ali Ulvi Önder
Published: (1998-06-01)

High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy
by: Jonathan W. Lischalk, et al.
Published: (2024-03-01)

Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study
by: Giovanni Tarantino, et al.
Published: (2021-03-01)

Prostatic Carcinoma: Frequency, Pattern and Evaluation of Gleason Grading in Prostate Biopsies
by: Uzma Bukhari, et al.
Published: (2020-09-01)

Prostatic Carcinoma: Frequency, Pattern and Evaluation of Gleason Grading in Prostate Biopsies
by: Uzma Bukhari, et al.
Published: (2020-09-01)

Integrating PSA Change with PSA Density Enhances Diagnostic Accuracy and Helps Avoid Unnecessary Prostate Biopsies
by: Yi-Ju Chou, et al.
Published: (2025-08-01)

Prostate Specific Antigen Level and Gleason Score in Indonesian Prostate Cancer Patients
by: Muhammad Imam Al Kautsar Herawan, et al.
Published: (2024-09-01)

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review
by: Finn Edler von Eyben, et al.
Published: (2024-04-01)

Misanian Men, are or aren't a Prostatic Adenocarcinoma?
by: Haider Qasim Alhelfi
Published: (2021-04-01)

Second to fourth digit ratio: its relationship with core cancer volume and Gleason score in prostate biopsy
by: Jin Kyu Oh, et al.
Published: (2012-10-01)

THE PROGNOSTIC VALUE OF BASELINE PSA BLOOD IN THE TREATMENT OF PROSTATE CANCER
by: A. A. Gritskevich, et al.
Published: (2017-02-01)

PSA DENSITY - A MARKER FOR POORLY-DIFFERENTIATED PROSTATE CANCER
by: Tosho Ganev
Published: (2025-02-01)

Histopathological Spectrum of Lesions Observed in Prostate Specimens - An Institutional Experience
by: Surbhi Mahajan, et al.
Published: (2023-10-01)

Correlation between Serum Prostate-Specific Antigen Level with Pathological Grade and Size of Prostate in Prostate Cancer Patients
by: Gamal A. Alsagheer, et al.
Published: (2025-01-01)

Relation between Serum Level of Total PSA and Free PSA/Total PSA Ratio with Grade of Prostate Cancer
by: Mohammad Yazdani, et al.
Published: (2013-10-01)

Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort
by: R. Jeffrey Karnes, et al.
Published: (2018-08-01)

Validation of the WHO 2016 new Gleason score of prostatic carcinoma
by: Vishal Rao, et al.
Published: (2018-01-01)

Correlation between Gleason Scores of Prostatic Biopsies and Radical Prostatectomy Specimens
by: Panitta Sitthinamsuwan, et al.
Published: (2009-01-01)

Diagnostic Efficacy of grey-zone Serum Prostate Specific Antigen level in patients with Benign Prostatic Hyperplasia and Prostate Carcinoma
by: Syed Atif Hussain, et al.
Published: (2025-01-01)

Prognostic Significance of the New Prostatic Carcinoma Grade Grouping System vis-àvis Biochemical Recurrence: Experience from a Tertiary Care Centre in Dakshina Kannada District, Karnataka, India
by: Anuradha Calicut Kini Rao, et al.
Published: (2021-07-01)

Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice
by: Bannakij Lojanapiwat
Published: (2014-09-01)

Prostate Cancer: Burden and Correlation with Prostate Specific Antigen Among Screened African Men in Tanzania
by: Ngowi BN, et al.
Published: (2024-11-01)

Microvessel density in Prostatic Lesions : Relevance to prognosis
by: P Upadhyaya, et al.
Published: (2016-03-01)

Diagnostic value of free-to-total PSA proportion and PSA density in prostate cancer detection for prostate volumes >= 100 cc
by: Murat Zor, et al.
Published: (2018-12-01)

Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
by: Juan A. Encarnación Navarro, et al.
Published: (2025-02-01)

Evaluation of the Cure about the Prostate Cancer Patients, Taking Radiothraphy According To the Result of the Prosecution Prostate Specific Antigen
by: Feryal Karaca, et al.
Published: (2018-10-01)

Upregulation of mitochondrial function is associated with advanced prostate cancer
by: Valentin Baumgartner, et al.
Published: (2025-03-01)

Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy
by: Nina Čamdžić, et al.
Published: (2021-02-01)

Histopathological Outcomes after Radical Prostatectomy for Prostate Cancer Based On a New Grading System
by: Borislav Spajić, et al.
Published: (2018-01-01)